Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis

Abstract

Human Kruppel-like factor 2 (KLF2) is a Cys2/His2 zinc-finger-containing transcriptional factor, which is involved in multiple cellular pathways. Utilizing gene expression profiling to identify aberrantly expressed genes in ovarian cancer, we found that KLF2 was significantly and specifically downregulated in ovarian tumors. After reintroducing KLF2 into ovarian cancer cell lines, we observed decreased cell growth and increased sensitivity to DNA damage-induced apoptosis. Analysis of genes that could be potential targets of KLF2 revealed that KLF2 negatively regulated WEE1 expression. WEE1 encodes a tyrosine kinase that regulates the G2/M cell cycle transition. Expression of KLF2 markedly repressed the transcription of WEE1 by directly binding to an SP1/CPBP motif located between −252 bp and the start codon of the WEE1 promoter. Both activation and zinc-finger domains of KLF2 were required for this suppression of Wee1 expression. In addition, we demonstrated that Wee1 expression prevents cancer cells from undergoing apoptosis in response to DNA damage; however, this resistance was abolished by coexpression of KLF2, which inhibits WEE1 transcription. Thus, the level of WEE1 is regulated by KLF2 and enhanced KLF2 expression sensitizes cells to DNA damage-induced apoptosis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Banerjee SS, Feinberg MW, Watanabe M, Gray S, Haspel RL, Denkinger DJ, Kawahara R, Hauner H and Jain MK . (2003). J. Biol. Chem., 278, 2581–2584.

  • Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D and Friedman SL . (2004). Cancer Res., 64, 3885–3891.

  • Bieker JJ . (2001). J. Biol. Chem., 276, 34355–34358.

  • Black AR, Black JD and Azizkhan-Clifford J . (2001). J. Cell. Physiol., 188, 143–160.

  • Buckley AF, Kuo CT and Leiden JM . (2001). Nat. Immunol., 2, 698–704.

  • Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson Jr HF, Vessella RL and Dong JT . (2003a). Am. J. Pathol., 162, 1349–1354.

  • Chen X, Whitney EM, Gao SY and Yang VW . (2003b). J. Mol. Biol., 326, 665–677.

  • Dekker RJ, van Soest S, Fontijn RD, Salamanca S, de Groot PG, VanBavel E, Pannekoek H and Horrevoets AJ . (2002). Blood, 100, 1689–1698.

  • Denkinger DJ, Cushman-Vokoun AM and Kawahara RS . (2001). Gene, 281, 133–142.

  • Dent P and Grant S . (2001). Clin. Cancer Res., 7, 775–783.

  • Elder RT, Yu M, Chen M, Zhu X, Yanagida M and Zhao Y . (2001). Virology, 287, 359–370.

  • Huddleson JP, Srinivasan S, Ahmad N and Lingrel JB . (2004). Biol. Chem., 385, 723–729.

  • Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, Kawabe T, Hasegawa Y, Shimokata K and Sekido Y . (2004). Cancer Res., 64, 3838–3843.

  • Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, Nunez Rodriguez N, Liang BC, Guha A, Martignetti JA, Friedman SL and Chan AM . (2004). Oncogene, 23, 5077–5083.

  • Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA and Friedman SL . (2004). Hepatology, 40, 1047–1052.

  • Kuo CT, Veselits ML, Barton KP, Lu MM, Clendenin C and Leiden JM . (1997). Genes Dev., 11, 2996–3006.

  • Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR and Shridhar V . (2003). J. Biol. Chem., 278, 23107–23117.

  • Li J, Wang Y, Sun Y and Lawrence TS . (2002). Radiat. Res., 157, 322–330.

  • Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA and Friedman SL . (2001). Science, 294, 2563–2566.

  • Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, LoBuglio AF, Lobo-Ruppert SM and Ruppert JM . (2004). Clin. Cancer Res., 10, 2709–2719.

  • Pendergast AM . (1996). Curr. Opin. Cell Biol., 8, 174–181.

  • Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA and Friedman SL . (2004). Gastroenterology, 126, 1090–1103.

  • Rowley R, Hudson J and Young PG . (1992). Nature, 356, 353–355.

  • SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, Gimbrone Jr MA, Garcia-Cardena G and Jain MK . (2004). J. Exp. Med., 199, 1305–1315.

  • Tourret J and McKeon F . (1996). Prog. Cell Cycle Res., 2, 91–97.

  • Vax VV, Gueorguiev M, Dedov II, Grossman AB and Korbonits M . (2003). Endocr. Relat. Cancer, 10, 397–402.

  • Wang Y, Decker SJ and Sebolt-Leopold J . (2004). Cancer Biol. Ther., 3, 305–313.

  • Wu J and Lingrel JB . (2004). Oncogene, 23, 8088–8096.

  • Yoon HS, Chen X and Yang VW . (2003). J. Biol. Chem., 278, 2101–2105.

  • Yuan H, Kamata M, Xie YM and Chen IS . (2004). J. Virol., 78, 8183–8190.

  • Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS and Yang VW . (2000). J. Biol. Chem., 275, 18391–18398.

  • Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE and Yang VW . (2004). Oncogene, 23, 395–402.

Download references

Acknowledgements

We thank Dr Frank Prendergasts for his continuing interest and support. This work was supported by the following grants: Department of Defense Ovarian Cancer Program (Grant No. OC030016) and Minnesota Ovarian Cancer Alliance grant (to DIS); Hong Kong RGC earmarked Research (Grant No. 2140302) (to YFW); Research Grants Council of the Hong Kong Special Administrative Region (Grant No. CUHK4133/02M).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David I Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, F., Zhu, Y., Huang, Y. et al. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene 24, 3875–3885 (2005). https://doi.org/10.1038/sj.onc.1208546

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208546

Keywords

This article is cited by

Search

Quick links